

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE THIRD QUARTER OF 2021

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**”), together with its subsidiaries (the “**Group**”), for the third quarter ended 30 September 2021.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the third quarter of 2021, under the norm of the Covid-19 epidemic control in China, the Company, together with its member medical institutions, was orderly engaged in its business development under the guidance of the Group’s strategic plan and achieved a stable growth in operating results. For the nine months ended 30 September 2021, the revenue of the Group increased by approximately 16% as compared with the corresponding period of 2020, the profit for the period increased by approximately 12%, and the profit for the period attributable to ordinary shareholders of the parent increased by approximately 12%. The Group’s operation and management situation is as follows:

In respect of finance and advisory business as at 30 September 2021, with the continuous efforts of intensive and meticulous implementations in various regions, as compared with the first half of 2021, interest-earning assets achieved a sustainable growth, while net interest margin and net interest spread both remained stable and assets quality remained in a good condition.

In respect of hospital group business, the Group continued to actively participate in integration and takeover of medical institutions of state-owned enterprises, and advanced the completion and consolidation of contracted projects in an orderly manner. As at 30 September 2021, 42 medical

institutions had been consolidated into the Company's financial statements with actual capacity over 10,330 beds. In the meanwhile, the Group continued its efforts to improve the development of discipline constructions, operation management and service capabilities of the member medical institutions, actively enhancing their service quality, management efficiency and operating performance.

In respect of health industry business, focusing on core medical resources, the Group actively launched the expansion of layout in internet-based healthcare, equipment maintenance, medical testing, health insurance and combination of medical care with elderly care business, etc., so as to complete the healthcare industry chain.

In respect of financing support, the Group actively took advantage of onshore and offshore financing instruments while ensuring its capital liquidity and prudent debt maturity structure. The average funding cost for the first three quarters of this year decreased slightly as compared to that of 2020.

In addition, references are made to the announcements of the Company dated 4 June 2019, 5 March 2020, 19 May 2020, 8 April 2021 and 16 September 2021 in relation to the issuance of the medium-term notes with an aggregate principal amount of RMB2.86 billion in the inter-bank market in the People's Republic of China (the "PRC") by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) ("Universal Leasing"), a wholly-owned subsidiary of the Company. In accordance with the relevant laws and regulations of the PRC, the unaudited consolidated financial information of Universal Leasing for the nine months ended 30 September 2021 (the "Universal Leasing Consolidated Financial Information") has been published on the websites of Shanghai Clearing House (www.shclearing.com) and China Foreign Exchange Trade System (www.chinamoney.com.cn) on 29 October 2021. The Company's board of directors would like to draw the attention of its shareholders and investors to the following principal financial data of Universal Leasing:

PRINCIPAL CONSOLIDATED FINANCIAL DATA OF UNIVERSAL LEASING

*Unit: Thousand Yuan
Currency: RMB*

	As at 30 September 2021 (unaudited)	As at 31 December 2020 (audited)
Total assets	70,800,103	61,156,280
Total equity	18,104,322	15,778,168
	For the nine months ended 30 September 2021 (unaudited)	For the nine months ended 30 September 2020 (unaudited)
Operating income	7,446,641	6,438,682
Profit for the period	1,665,464	1,565,527
Net cash flows from / (used in)	(1,496,368)	1,565,189

operating activities

The Company hereby reminds investors that the above unaudited operation summary for the third quarter ended 30 September 2021 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group. The Universal Leasing Consolidated Financial Information was prepared in accordance with the General Accepted Accounting Principles of the PRC, which may require adjustment during the course of auditing of the financial results of the Group, and the information contained therein is limited solely to the operation of Universal Leasing, which does not provide a full picture of the operation status of the Group or comparison with the Group.

Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Peng Jiahong
Chairwoman of the Board

Beijing, PRC, 29 October 2021

As at the date of this announcement, the executive Directors are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Mr. Yu Gang; the non-executive Directors are Mr. Zhao Yan (Vice-chairman), Mr. Tong Chaoyin, Mr. Feng Songtao and Mr. Zhu Ziyang; and the independent non-executive Directors are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Han Demin and Mr. Liao Xinbo.